No Data
No Data
Buy Rating on Dianthus Therapeutics Supported by Promising MMN Treatment Data and Market Potential
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
DNTH103 is a monoclonal antibody in clinical development.
Dianthus Therapeutics: Katkhuda's Buy Rating Backed by Promising DNTH103 Clinical Prospects and Strategic Positioning
Dianthus Therapeutics Announces Two Poster Presentations For DNTH103 At The 10th Congress Of The European Academy Of Neurology June 29-July 2, 2024
Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, to
Express News | Dianthus Therapeutics Shares Are Trading Higher After Cantor Fitzgerald Initiated Coverage on the Stock With an Overweight Rating
Dianthus Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dianthus Therapeutics Initiated at Overweight by Cantor Fitzgerald